Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

737 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial.
Salamanca de la Cueva I, Pahud B, Huang LM, Leonardi M, Garcia-Sicilia J, Céspedes J, Abdelnour A, Tamura T, Kuroki H, Chiu NC, Virta M, Kokko S, Horn M, Panzer F, Kim JH, Jin L, Moerman L, Debacq C, Parra J, Ugarte A, Bi D; Rota-081 Study Group. Salamanca de la Cueva I, et al. Among authors: bi d. J Infect Dis. 2020 May 4;225(12):2106-15. doi: 10.1093/infdis/jiaa210. Online ahead of print. J Infect Dis. 2020. PMID: 32365189 Free PMC article.
Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial.
Abu-Elyazeed R, Klein NP, Moerman L, Povey M, Pruitt A, Senders S, Silas P, Bi D; Rota-090 Study Group. Abu-Elyazeed R, et al. Among authors: bi d. Vaccine. 2021 Mar 5;39(10):1534-1543. doi: 10.1016/j.vaccine.2020.08.070. Epub 2020 Oct 17. Vaccine. 2021. PMID: 33077301 Free article. Clinical Trial.
Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.
Lau YL, Fan Leung T, Sirvan Cetin B, Cagri Dinleyici E, Huang LM, Halperin SA, Hsiao CC, Tapiero B, Tipton M, Campbell JD, Moerman L, Povey M, Bi D, Singh T; Rota-096 study group. Lau YL, et al. Among authors: bi d. Vaccine. 2022 Mar 25;40(14):2184-2190. doi: 10.1016/j.vaccine.2022.02.065. Epub 2022 Feb 26. Vaccine. 2022. PMID: 35232596 Free article. Clinical Trial.
A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants.
Cohet C, Cheuvart B, Moerman L, Bi D, Caplanusi A, Kariyappa M, Lalwani S, Mitra M, Sapru A, Saha S, Varughese PV, Kompithra RZ, Gandhi S. Cohet C, et al. Among authors: bi d. Hum Vaccin Immunother. 2021 Nov 2;17(11):4646-4653. doi: 10.1080/21645515.2021.1960136. Epub 2021 Aug 24. Hum Vaccin Immunother. 2021. PMID: 34428112 Free PMC article. Clinical Trial.
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Among authors: bi d. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, Pukkala E, Angelo MG, Zima J, David MP, Datta S, Bi D, Struyf F, Dubin G. Lehtinen M, et al. Among authors: bi d. Hum Vaccin Immunother. 2016 Dec;12(12):3177-3185. doi: 10.1080/21645515.2016.1183847. Hum Vaccin Immunother. 2016. PMID: 27841725 Free PMC article. Clinical Trial.
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, Yang X, Yu JX, Zhu J, Zhu Y, Chen F, Zhang Q, Wang H, Wang C, Bi J, Xue S, Shen L, Zhang YS, He Y, Tang H, Karkada N, Suryakiran P, Bi D, Struyf F. Zhu FC, et al. Among authors: bi d, bi j. Cancer Med. 2019 Oct;8(14):6195-6211. doi: 10.1002/cam4.2399. Epub 2019 Jul 15. Cancer Med. 2019. PMID: 31305011 Free PMC article. Clinical Trial.
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.
Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, Yang X, Yu JX, Zhu J, Zhu Y, Chen F, Zhang Q, Wang H, Wang C, Bi J, Xue S, Shen L, Zhang YS, He Y, Tang H, Karkada N, Suryakiran P, Bi D, Struyf F. Zhu FC, et al. Among authors: bi d, bi j. Cancer Med. 2017 Jan;6(1):12-25. doi: 10.1002/cam4.869. Epub 2016 Dec 20. Cancer Med. 2017. PMID: 27998015 Free PMC article. Clinical Trial.
737 results